----item----
version: 1
id: {9F868187-7622-4CA6-9001-5065B5D70521}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/09/11/Video BioNTechs Marett On Sanofi Deal And Immunotherapy
parent: {62C55766-C278-4043-A2CE-96E19F97E9EA}
name: Video BioNTechs Marett On Sanofi Deal And Immunotherapy
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: f9a6aca5-6018-47d0-a073-8b9b386997dc

----field----
field: {0212FC0F-953B-461C-B4D9-B7483A4D4F1B}
name: Taxonomy
key: taxonomy
content-length: 38

{728904A1-7259-48E8-8256-60D002A0BFEA}
----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 60

 Video: BioNTech's Marett On Sanofi Deal And Immunotherapy  
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 55

Video BioNTechs Marett On Sanofi Deal And Immunotherapy
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 1460

<p> In this video interview BioNTech chief operating officer, Sean Marett, discusses his company's recent Sanofi immunotherapy deal with Mike Ward, global director of content for Informa Pharma Insights, at BIO-Europe in Munich, Germany. They chat about BioNTech's messenger RNA technology, co-development plans with Sanofi and the potential for immunotherapy combination studies. </p> <p> <preform><iframe src="http://api.medianac.com/p/116/sp/11600/embedIframeJs/uiconf_id/11601339/partner_id/116?iframeembed=true&playerId=kaltura_player_1447669666&entry_id=0_9e7x5fzx&flashvars[streamerType]=rtmp&flashvars[mediaProtocol]=rtmp" allowfullscreen="" webkitallowfullscreen="" mozallowfullscreen="" frameborder="0" itemprop="video" itemscope="" itemtype="http://schema.org/VideoObject"> <span itemprop="name" content="BEU15 Interview Sean Marett"></span> <span itemprop="description" content=""></span> <span itemprop="duration" content="580"></span> <span itemprop="thumbnail" content="http://api.medianac.com/p/116/sp/11600/thumbnail/entry_id/0_9e7x5fzx/version/100002/acv/132"></span> <span itemprop="width" content="560"></span> <span itemprop="height" content="315"></span> </iframe> </preform></p> <p> Look out for more BIO-Europe exclusive interviews all this week on <i>Scrip</i>. To see more video interviews and panel discussions from BIO-Europe 2015 right now visit <a href="http://www.partnering360.com/insight" target="_new">Partnering360</a>. </p> 
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 385

<p> In this video interview BioNTech chief operating officer, Sean Marett, discusses his company's recent Sanofi immunotherapy deal with Mike Ward, global director of content for Informa Pharma Insights, at BIO-Europe in Munich, Germany. They chat about BioNTech's messenger RNA technology, co-development plans with Sanofi and the potential for immunotherapy combination studies. </p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 55

Video BioNTechs Marett On Sanofi Deal And Immunotherapy
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150911T210000
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150911T210000
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150911T210000
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC030319
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 60

 Video: BioNTech's Marett On Sanofi Deal And Immunotherapy  
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{090E9A04-9B4B-4986-8BAF-06A6B07B978D}
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 11

Expert View
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

361479
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042523Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

f9a6aca5-6018-47d0-a073-8b9b386997dc
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042523Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
